Renee A.
She codes diabetic complication charts every day. She watched her father lose a foot. She was next — until she wasn't.
A1c from 8.4 to 5.3. Microalbuminuria resolved. Off glipizide entirely. 51 lbs lost. Type 2 diabetes in clinical remission — without insulin, without surgery, and without the future she was terrified of inheriting.
She Knew Exactly Where This Was Heading
Renee is a 49-year-old senior medical coding specialist at a regional hospital — married 24 years, mother of two adult children, 100% remote since 2020. Her workday means 9+ hours stationary at a desk, followed by 4–5 hours of screen time in the evening. The small movements that once came with commuting and office life had been gone for years. She and her husband had been in a "we'll start Monday" pattern going back longer than either of them cared to admit.
Renee was diagnosed with Type 2 diabetes six years ago at an A1c of 6.4. Metformin was started. For three years, control was decent. Then her A1c climbed despite the metformin. Glipizide was added two years ago. By the time she came to FLOA, her A1c was 8.4 — and her last PCP visit had produced the words she had been dreading: insulin was the next step. She also had microalbuminuria — the earliest stage of diabetic kidney damage.
Renee codes diabetic complication charts every single workday. She knows the trajectory: neuropathy, retinopathy, kidney disease, amputation. Her father died of diabetic complications at 72 after losing a foot. Her mother has Type 2. A paternal aunt has Type 2. She came to FLOA not looking for motivation. She came looking for a protocol that could actually change the biological outcome she was heading toward.
What Six Years of Worsening T2D Looked Like
- A1c 8.4% — poor control on two oral medications; insulin conversation already started
- Fasting glucose 168 mg/dL; postprandial glucose frequently above 200 on home glucometer
- Extreme insulin resistance: HOMA-IR 9.9, fasting insulin 24 mIU/L — the classic T2D locked-gas-cap pattern
- Microalbuminuria: UACR 38 mg/g — earliest stage of diabetic kidney damage already present
- hs-CRP 5.1 mg/L — significant systemic inflammation driving and driven by metabolic dysfunction
- ALT 48 — borderline NAFLD pattern, consistent with hepatic insulin resistance
- Weight 226 lbs at 5'4" — BMI 38.8, Class 2 obesity; 6 years without structured exercise
- Waist circumference 47 inches — central adiposity pattern typical of advanced insulin resistance
- Three generations of T2D complications in immediate family — father deceased from complications at 72
- Completely sedentary remote workday — no meaningful movement in 6 years
- Evening snacking and weekend restaurant eating identified as primary Diet Leaks
- Perimenopausal symptoms beginning — deferred for treatment until metabolic stabilization achieved
A Diabetes-First, Medically Coordinated Approach
Fasting insulin, HOMA-IR, A1c, fructosamine, full lipid panel including ApoB, hs-CRP, complete kidney function (creatinine, eGFR, UACR), liver enzymes, full thyroid panel, vitamin D, and B12 (chronic metformin depletes B12). Seven-day food log audit identifying specific Diet Leaks. Cortisol curve assessment. PCP coordination established from day one — essential for glipizide taper management to prevent hypoglycemia as glucose normalized.
Semaglutide chosen over tirzepatide specifically for this case — it carries the strongest FDA-approved indication and SUSTAIN trial evidence base for Type 2 diabetes, making PCP coordination and documentation cleaner. Started at 0.25mg, escalated steadily with simultaneous glipizide tapering coordinated with her PCP to prevent hypoglycemia. No fasting protocol introduced in months 1–4 while glipizide was still active — fasting on a sulfonylurea carries real hypoglycemia risk. Fasting window introduced only after glipizide discontinuation at month 4.
AOD-9604 added at month 2 once semaglutide tolerance was confirmed and glipizide was discontinued. Supply-side fat mobilization to complement the GLP-1's demand-side appetite control — targeting the central adiposity pattern that insulin resistance preferentially drives. At HOMA-IR 9.9, visceral fat mobilization required direct intervention beyond appetite suppression alone.
CJC-1295/Ipamorelin added at month 3 for two specific purposes: lean mass preservation during an aggressive diabetic-reversal trajectory, and sleep architecture improvement. Patients losing significant weight rapidly on GLP-1 + caloric deficit are at real risk of lean mass erosion. Preserving lean mass protects metabolic rate and insulin sensitivity long-term — outcomes that matter enormously for sustained T2D remission.
Continuous glucose monitoring trial at month 2 made the food-glucose relationship visible in real time — replacing abstract dietary rules with direct feedback. Protein First nutrition targeting 130g/day. Evening snacking eliminated. Weekend restaurant eating brought into structure. The CGM transformed her relationship with food from anxiety-driven avoidance to informed decision-making — critical for someone who had been living with glucose fear for 6 years.
Exercise prescription built around her actual baseline — six years completely sedentary — not an idealized starting point. Month 1: 10-minute walks 3x daily. Month 3: 30-minute walks plus two short strength sessions weekly. Month 6: full strength training program. No aggressive exercise prescription imposed on a body that hadn't moved in 6 years. The progression matched her physiology, not a generic protocol.
Phase by Phase
Fasting Glucose Drops 36 Points in 3 Weeks
Semaglutide initiated at 0.25mg. Down 6 lbs. Fasting glucose dropped from 168 to 132 mg/dL within 3 weeks — the most rapid glucose response Renee had seen in 6 years of medication management. Glipizide reduced from 5mg to 2.5mg in coordination with her PCP. 10-minute walks three times daily introduced — the first structured movement in 6 years.
→ Down 6 lbs; fasting glucose 132; glipizide halved; walking started
Off Glipizide — Fasting Glucose Averaging 110
Titrated to 0.5mg. AOD-9604 added. Down 13 lbs. Glipizide discontinued entirely — a meaningful milestone both clinically and psychologically. Fasting glucose averaging 110 mg/dL on semaglutide alone. CGM trial initiated: the food-glucose relationship made visible in real time for the first time. Food anxiety beginning to shift to informed confidence.
→ Down 13 lbs; off glipizide; fasting glucose 110; CGM clarity established
A1c Back to Diagnosis Baseline — CJC-1295/Ipamorelin Added
Titrated to 1.0mg. CJC-1295/Ipamorelin added for lean mass preservation and sleep improvement. Down 21 lbs. A1c rechecked at 6.4% — exactly her original diagnosis baseline from 6 years prior, now descending rather than climbing. Strength training sessions introduced twice weekly. The trajectory had fully reversed.
→ Down 21 lbs; A1c 6.4 and falling; strength training started
Out of Diabetic Range — Microalbuminuria Reducing
Held at 1.0mg semaglutide — no further escalation needed. Down 32 lbs. A1c 5.9% — for the first time in 6 years, out of the diabetic range and into prediabetic. Microalbuminuria reducing: UACR from 38 to 22 mg/g. The kidney damage that had terrified her most was beginning to reverse. Fasting window (14:10) introduced now that glipizide was gone.
→ Down 32 lbs; A1c 5.9% (out of diabetic range); UACR 22
Clinical Diabetes Remission — Metformin Reduction Begins
Down 44 lbs. A1c 5.5% — clinical T2D remission by standard criteria. Metformin reduced from 1000mg twice daily to 500mg twice daily in coordination with her PCP. She was no longer the patient she codes about every day. Full strength training program in place. The conversation with her husband about his own health had begun in earnest.
→ Down 44 lbs; A1c 5.5% (T2D remission); metformin reduced
51 lbs Lost — Microalbuminuria Resolved — A1c 5.3%
226 → 175 lbs. A1c 5.3%. UACR 14 mg/g — microalbuminuria fully resolved, within normal range. Waist 35 inches, down from 47. InBody confirmed 43 lbs fat lost, 8 lbs lean mass preserved. Long-term plan set: microdose semaglutide, continued metformin as a hedge, quarterly monitoring. BHRT conversation reopened for perimenopausal symptoms now that metabolic foundation was secure.
→ 51 lbs lost; A1c 5.3%; microalbuminuria resolved; waist 35″
"Renee's HOMA-IR was 9.9. Her cells had become so insulin-resistant that her pancreas was pumping out 24 mIU/L of insulin just to maintain a fasting glucose of 168. Adding glipizide to that environment — forcing a failing pancreas to produce even more insulin — is like flooring the accelerator on a car with the parking brake engaged. GLP-1 therapy doesn't just lower glucose. It breaks the insulin resistance cycle at the receptor level, which is the only way to actually reverse the disease rather than manage its progression."
What Changed at 12 Months
Diabetes Reversed
A1c from 8.4 → 5.3% — clinical T2D remission. Off glipizide entirely. Metformin reduced. Insulin never started. The disease trajectory her family history had written — rewritten.
Kidney Damage Reversed
Microalbuminuria: UACR from 38 → 14 mg/g — fully resolved and within normal range. The earliest stage of diabetic kidney damage that had sent Renee to FLOA in the first place, no longer present.
Body Composition
51 lbs lost over 12 months. 43 lbs fat, 8 lbs lean mass preserved per InBody — strong lean mass retention for an aggressive diabetic-reversal trajectory. Waist from 47 → 35 inches.
Insulin Resistance Resolved
HOMA-IR from 9.9 → 1.5. Fasting insulin from 24 → 7 mIU/L. The extreme insulin resistance driving the entire metabolic picture — normalized to near-optimal range.
Inflammation & Liver
hs-CRP from 5.1 → 1.0 mg/L. ALT from 48 → 22 — borderline NAFLD pattern resolved. Systemic inflammatory burden that had been driving and driven by the metabolic dysfunction substantially cleared.
Physical Function Restored
From 6 years completely sedentary to a full strength training program by month 6. Daily walks built in. Physical capacity reclaimed in a body that had stopped moving entirely during the remote work years.
| Category | What Changed |
|---|---|
| Diabetes Status | Active T2D on two medications → clinical remission; A1c 8.4 → 5.3% |
| Glipizide | 5mg daily → discontinued entirely by month 2 |
| Insulin | Next-step recommendation → never started |
| Microalbuminuria | UACR 38 → 14 mg/g — kidney damage fully resolved |
| Fasting Glucose | 168 mg/dL → averaging 95–105 mg/dL at month 12 |
| Waist | 47 inches → 35 inches — 12 inches of central adiposity lost |
| Exercise | Zero structured movement for 6 years → full strength training program by month 6 |
| Food Anxiety | Glucose fear replaced by CGM-informed confidence and sustainable food structure |
| Family Legacy | Father's trajectory — loss of foot, death at 72 — no longer Renee's trajectory |
| Her Husband | Honest conversation about his own health opened for the first time; now exploring his own protocol |
"I code diabetic complication charts every day. I know what neuropathy looks like on paper. I know what an amputation code looks like. I watched my father die at 72 from this disease after losing his foot. When my doctor said insulin was next, I knew I was on the same road. FLOA was the first place that treated my diabetes as something that could actually be reversed — not just managed until it got worse. A year later my A1c is 5.3, my kidney damage is gone, I've lost 51 pounds, and I am not my father's story."
Clinical Takeaways
Renee's case exposes the fundamental limitation of the conventional T2D escalation pathway: adding medications to manage a progressively failing system without addressing the underlying insulin resistance that is driving the failure. At HOMA-IR 9.9 and fasting insulin of 24, Renee's pancreas was working at maximum capacity to overcome cellular insulin resistance — and glipizide was demanding it work even harder. The glucose numbers were being partially managed. The disease was still progressing. Microalbuminuria doesn't develop in a well-controlled patient.
GLP-1 therapy with semaglutide addressed the actual mechanism. By improving insulin sensitivity at the receptor level, reducing hepatic glucose production, slowing gastric emptying, and driving meaningful weight loss — particularly of visceral and hepatic fat — it created the conditions under which the body could begin to heal rather than just compensate. The addition of AOD-9604 for visceral fat mobilization and CJC-1295/Ipamorelin for lean mass preservation and sleep meant the protocol was not just treating glucose. It was treating the full metabolic environment.
The medication coordination with her PCP was not optional — it was essential. Glipizide forces insulin secretion regardless of glucose level; introducing a fasting protocol or aggressive caloric reduction while a patient is on a sulfonylurea carries serious hypoglycemia risk. The sequencing — semaglutide first, glipizide taper coordinated with glucose normalization, fasting introduced only after glipizide was gone — reflects the clinical caution that complex diabetic cases require. Getting the sequence right was as important as getting the medications right.
Type 2 Diabetes Is Not Inevitable — and Neither Is the Escalation
Adding a second medication when the first stops working is not a plan. It is a delay. If you have Type 2 diabetes and you're watching your A1c climb despite medication, the question worth asking is whether anyone has actually tried to reverse the underlying insulin resistance — or just manage the number.
Individual results vary. This case study is for educational purposes only. © Dr. Jones DC — FLOA Protocol.